Status:
UNKNOWN
PD-L1 Expression in Cancer (PECan Study).
Lead Sponsor:
Guy's and St Thomas' NHS Foundation Trust
Collaborating Sponsors:
NanoMab Technology (UK) Limited
Conditions:
Non-small Cell Lung Cancer
Melanoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Measurement of PD-L1 expression in cancer to monitor treatment response. A prospective non-blinded, single centre, single interventional arm diagnostic imaging study. To determine the baseline level...
Detailed Description
Using \[99mTc\]-labeled anti-PD-L1 single-domain antibody, this study aims to prospectively measure changes in PD-L1 expression determined with SPECT/CT imaging and correlate these changes with respon...
Eligibility Criteria
Inclusion
- Aged 18 or above
- Patients with histologically confirmed NSCLC or melanoma scheduled for PD1/PDL1 immunotherapy alone or in combination with other systemic anti-cancer therapy.
- Willingness and ability to comply with scheduled study visits and tests.
Exclusion
- Pregnant or lactating women
- Concomitant uncontrolled medical conditions
- Patients likely to require palliative radiotherapy within the first 12 weeks of treatment or radiotherapy to target lesion(s) received within preceding 42 days
- More than 3 months between IHC PDL1 and study recruitment
- Patients who have received other systemic anti-cancer therapy within preceding 14 days
- Prognosis less than 3 months
- Previous anticancer treatment with any checkpoint inhibitor or other immunotherapy, i.e. only immunotherapy naïve patients
Key Trial Info
Start Date :
March 11 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04436406
Start Date
March 11 2020
End Date
January 31 2024
Last Update
December 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom